IP Library Granted Patent US 7,989,584
Granted Patent B2
US 7,989,584 · App. 12/633,984 · Granted Aug 2, 2011

AKT nucleic acids, polypeptides, and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,989,584
App. No.
12/633,984
Granted
Aug 2, 2011
Kind
B2
Abstract

The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis.

Claims (11)

1. An isolated human Akt3 protein comprising the sequence Cys-GIn-GIn-Ser-Asp-Cys-Gly-Met-Leu-Gly-Asn-Trp-Lys-Lys (residues 452-465 of SEQ ID NO:2) wherein the protein has a property selected from the following:

A. it is encoded by a nucleic acid comprising SEQ ID NO:1;

B. it comprises the amino acid sequence as depicted in SEQ ID NO:2; and

C. it specifically binds to an antibody generated against an epitope within a peptide consisting of the sequence Cys-GIn-GIn-Ser-Asp-Cys-Gly-Met-Leu-Gly-Asn-Trp-Lys-Lys (residues 452-465 of SEQ ID NO:2).

2. The isolated protein of claim 1 comprising the amino acid sequence as depicted in SEQ ID NO:2.

3. The isolated protein according to claim 1 , further comprising a tag sequence.

4. The isolated protein according to claim 3 , further comprising a myristylation sequence.

5. An antigenic peptide consisting of the sequence Cys-GIn-GIn-Ser-Asp-Cys-Gly-Met-Leu-Gly-Asn-Trp-Lys-Lys (residues 452-465 of SEQ ID NO:2) or an antigenic fragment thereof.

6. An isolated protein comprising the sequence Cys-Gln-Gln-Ser-Asp-Cys-Gly-Met-Leu-Gly-Asn-Trp-Lys-Lys (residues 452-465 of SEQ ID NO:2).

7. The isolated protein according to claim 6 , further comprising a tag sequence.

8. The isolated protein according to claim 7 , further comprising a myristylation sequence.

Assignments (5)
MERGER Recorded Jan 19, 2015
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034781/0334 →
CERTIFICATE OF CONVERSION Recorded Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034566/0976 →
CHANGE OF NAME Recorded Feb 17, 2011
From: RHONE-POULENC RORER PHARMACEUTICALS INC.
To: AVENTIS PHARMACEUTICALS PRODUCTS INC.
Reel/Frame 025821/0917 →
CHANGE OF NAME Recorded Feb 17, 2011
From: AVENTIS PHARMACEUTICALS PRODUCTS INC.
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 025821/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2011
From: GUO, KUN; CLARK, KENNETH L.; IVASHCHENKO, YURI D.; PAGNONI, MARCO
To: RHONE-POULENC RORER PHARMACEUTICALS INC.
Reel/Frame 025819/0475 →